Long Term Study of VAH631 in Patients With Essential Hypertension (Extension From B1303 Study)

• Status: Completed
• Trial end date: 2007-09-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to provide long-term safety and efficacy data for the combination doses of VAH (VAL/ HCTZ) 40/6.25mg and 80/12.5mg in essential hypertensive patients. The 350 patients (approximately) who have successfully finished the core trial CVAH631B1303 and signed consent for the extension will be enrolled into this study.

• Phase: Phase 3

Details

• Lead Sponsor: Novartis
• Treatments: Hydrochlorothiazide; Valsartan

Criteria

Inclusion Criteria:

• Patients who successfully complete the core study (Protocol 1303)

• Outpatients

Exclusion Criteria:

• Presence of crucial protocol violation in Protocol 1303

• Patients who experienced any adverse events considered serious and drug related in Protocol 1303.